Veracyte, Inc. VCYT R2KR3KPHARMA
Company Overview
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
Why Investors Should Care
Revenue has grown at a 45.8% CAGR over the past five years.
Maintains a net profit margin of 20.4%.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $517.14M (+16.0% YoY); net profit $66.35M.
- Trailing 12 Months Year-on-year growth — revenue +15.5%, earnings +174.9%.
- 5-Year Trend Long-term compounding — revenue CAGR 45.8%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 45.77% |
| 1 Year: | 15.50% |
Compounded Profit Growth
| 5 Years: | - |
| 1 Year: | 174.89% |
Stock Price Performance
| 1 Year: | +41.49% |
| 6 Months: | +28.24% |
| 3 Months: | -10.92% |
| 1 Month: | -5.94% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMAAbove
- RSI (14)42.89 · Neutral
P/E of 31.01 is above the sector median of 25.17 — pricier than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Excellent profit margin of 20.4%.
- Compounding revenue at 45.8% over 5 years.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading 28.2% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | VCYT Veracyte, Inc. R2KR3KPHARMA | 43.41 | 31.01 | $3.49B | 0.00% | 4.29% | 8.77% | 45.77% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2014 | Mar 2015 | Jun 2015 | Sep 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | 16.43M | 18.41M | 17.52M | 19.60M | 20.04M | 22.75M | 23.47M | 25.75M | 29.53M | 30.14M | 30.97M | 29.73M | 31.12M | 20.70M | 31.12M | 34.54M | 36.70M | 55.10M | 60.37M | 67.78M | 72.86M | 75.59M | 82.42M | 90.32M | 90.11M | 96.84M | 114.43M | 115.86M | 114.47M | 130.16M | 131.87M | 139.07M | 150.32M |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 55.82M | 57.69M | 62.47M | 77.91M | 79.01M | 79.51M | 89.77M | 91.28M | 101.16M | 108.55M |
| Operating Income | -7.81M | -7.55M | -9.07M | -8.89M | -9.75M | -10.49M | -4.89M | -7.52M | -6.61M | -6.37M | - | -8.96M | -5.92M | -4.30M | - | -2.07M | -3.10M | -1.76M | - | -12.20M | -11.05M | -4.07M | - | -45.41M | -7.47M | -16.68M | -15.25M | -10.73M | -9.68M | -10.50M | -8.05M | -31.74M | -4.66M | 4.61M | 12.02M | 2.90M | -5.27M | 22.95M | 22.65M | 22.98M |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -1.92M | -2.49M | -730.00K | -7.46M | -11.72M | -11.03M | -4.12M | -8.04M | -41.87M | -9.04M | -14.13M | -14.46M | -9.53M | -8.72M | -8.09M | -8.40M | -29.62M | -1.86M | 5.73M | 15.15M | 7.05M | -980.00K | 19.14M | 28.71M | 25.49M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.22 | -0.08 | - | -0.66 | -0.13 | -0.20 | -0.20 | -0.13 | -0.12 | -0.11 | -0.12 | -0.41 | -0.02 | 0.07 | 0.19 | 0.09 | -0.01 | 0.24 | 0.35 | 0.31 |
| R&D Expense | 2.23M | 2.79M | 3.10M | 3.56M | 3.46M | 4.27M | 4.01M | 4.03M | 3.60M | 3.05M | - | 3.67M | 4.60M | 3.42M | - | 3.44M | 3.33M | 3.64M | - | 4.41M | 4.17M | 4.04M | - | 5.34M | 6.25M | 8.01M | 9.17M | 9.38M | 10.77M | 12.77M | 12.54M | 13.32M | 15.96M | 16.46M | 17.57M | 17.72M | 16.26M | 15.98M | 27.10M | 29.44M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.65M | 11.63M | 21.88M | 38.19M | 49.50M | 65.08M | 71.95M | 92.01M | 120.37M | 117.48M | 219.51M | 296.54M | 361.05M | 445.76M | 517.14M |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | 175.68M | 229.68M | 298.14M | 362.53M |
| Operating Income | -15.27M | -18.93M | -23.17M | -29.01M | -33.47M | -28.80M | -26.54M | -22.23M | -15.13M | -35.39M | -81.90M | -41.08M | -85.80M | 16.14M | 57.78M |
| Net Income | -14.45M | -18.65M | -25.58M | -29.37M | -33.70M | -31.36M | -31.00M | -23.00M | -12.60M | -34.91M | -75.56M | -36.56M | -74.40M | 24.14M | 66.35M |
| Diluted EPS | - | - | - | - | - | - | - | - | -0.27 | -0.66 | -1.11 | -0.51 | -1.02 | 0.31 | 0.82 |
| R&D Expense | 6.68M | 6.61M | 7.81M | 9.80M | 12.80M | 15.32M | 13.88M | 14.82M | 14.85M | 17.20M | 29.84M | 40.60M | 57.30M | 69.29M | 70.81M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 19.07M | 79.63M | 64.84M | 75.25M | 101.03M | 78.67M | 120.64M | 275.21M | 457.16M | - | 1.16B | 1.11B | 1.30B | 1.41B |
| Current Assets | - | - | - | - | - | - | - | - | - | - | - | - | 248.64M | 285.62M | 372.27M | 488.38M |
| Cash & Equivalents | 2.77M | 7.57M | 14.00M | 71.22M | 35.01M | 39.08M | 59.22M | 33.89M | 78.00M | 159.32M | 349.36M | - | 154.25M | 216.45M | 239.09M | 362.58M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - | 14.29M | 16.13M | 21.75M | 20.55M |
| Receivables | - | - | - | - | - | - | - | - | - | - | - | - | 44.02M | 40.38M | 46.52M | 44.66M |
| Total Liabilities | - | - | 14.17M | 23.19M | 23.46M | 24.00M | 41.45M | 41.44M | 40.88M | 35.76M | 35.93M | - | 81.22M | 70.80M | 124.07M | 96.44M |
| Current Liabilities | - | - | 8.99M | 15.39M | 17.14M | 14.72M | 11.53M | 12.03M | 13.06M | 17.47M | 16.78M | - | 62.61M | 61.24M | 78.63M | 59.94M |
| Long Term Debt | - | - | - | 4.90M | 4.92M | 4.99M | 24.92M | 24.94M | 23.93M | 694.00K | 810.00K | - | - | - | - | - |
| Total Debt | - | - | - | - | - | - | - | - | - | - | - | - | 14.72M | 12.63M | 50.74M | 39.65M |
| Total Equity | -26.81M | -40.77M | -58.47M | 56.44M | 41.37M | 51.25M | 59.58M | 37.23M | 79.75M | 239.46M | 421.23M | - | 1.08B | 1.04B | 1.18B | 1.31B |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | - | 71.96M | 73.26M | 77.77M | 79.36M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | -26.96M | -27.98M | -23.91M | -13.52M | -3.23M | -9.71M | - | 7.54M | 44.22M | 75.10M | 136.31M |
| Investing Cash Flow | - | - | - | - | -6.70M | -4.21M | -1.31M | -1.87M | -42.73M | -3.84M | - | -29.39M | 15.11M | -56.27M | -9.21M |
| Financing Cash Flow | - | - | - | - | 37.73M | 52.33M | -218.00K | 59.50M | 127.29M | 203.59M | - | 3.49M | 2.84M | 4.90M | -4.22M |
| Capital Expenditure | -276.00K | -1.46M | -1.33M | -2.02M | -6.17M | -4.21M | -1.75M | -1.87M | -2.76M | -2.84M | - | -8.55M | -9.96M | -11.29M | -9.68M |
| Free Cash Flow | - | - | - | - | -33.13M | -32.19M | -25.67M | -15.39M | -5.99M | -12.55M | - | -1.01M | 34.26M | 63.81M | 126.63M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - | - | -18.36M | 62.17M | 23.73M | 122.88M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | 59.2% | 63.6% | 66.9% | 70.1% |
| Operating Margin % | -577.2% | -162.8% | -105.9% | -76.0% | -67.6% | -44.3% | -36.9% | -24.2% | -12.6% | -30.1% | -37.3% | -13.9% | -23.8% | 3.6% | 11.2% |
| Net Margin % | -546.1% | -160.4% | -116.9% | -76.9% | -68.1% | -48.2% | -43.1% | -25.0% | -10.5% | -29.7% | -34.4% | -12.3% | -20.6% | 5.4% | 12.8% |
| ROE % | 35.4% | 31.9% | -45.3% | -71.0% | -65.8% | -52.6% | -83.3% | -28.8% | -5.3% | -8.3% | - | -3.4% | -7.1% | 2.1% | 5.1% |
| ROCE % | - | -187.9% | -36.1% | -60.8% | -55.3% | -32.2% | -39.8% | -20.7% | -5.9% | -8.0% | - | -3.8% | -8.1% | 1.3% | 4.3% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 16.78% | 13.49M | $584.50M |
| 2 | FMR, LLC | 9.58% | 7.70M | $333.84M |
| 3 | Artisan Partners Limited Partnership | 6.89% | 5.54M | $240.03M |
| 4 | Vanguard Portfolio Management LLC | 5.87% | 4.72M | $204.40M |
| 5 | State Street Corporation | 5.84% | 4.70M | $203.62M |
| 6 | Vanguard Capital Management LLC | 4.47% | 3.59M | $155.76M |
| 7 | Dimensional Fund Advisors LP | 3.52% | 2.83M | $122.50M |
| 8 | First Trust Advisors LP | 3.12% | 2.51M | $108.69M |
| 9 | ARK Investment Management, LLC | 2.86% | 2.30M | $99.51M |
| 10 | Wellington Management Group, LLP | 2.83% | 2.27M | $98.56M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for VCYT
Veracyte (VCYT) CFO stock sale alongside tax share withholding - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiqgFBVV95cUxObm5aRHBwWElOS3J4ZmxPdWlFRXJpWUNCX2g0S3dKRkNsU1o1aERNRzlNd1BXX1UwTDJEQlViRm54MTdfYVBwSmpoUWxOc0pwZDBJQklWT1NOc1BXTUVTanpLVVVWRHFFbm1tWlNZbm9QWHZfTmQyOHh0aFlIUHh6X3FQdWxRdm11OC1nNj…
Veracyte Inc (VCYT) Shares Fall 4.8% -- GF Value Says Still Over - GuruFocus
<a href="https://news.google.com/rss/articles/CBMipAFBVV95cUxOekYxNmU4ang0ajIyUGhoMlpNbFFRQTR0VEJMRXIzUVM1aWJfM0x2X21lV282Wk4wdUJDakpWVlNEbjZET3lUS0VMNE9KVVZZQlRXS3J3SGNFcVpYMEdyLWY5aFZTVmc1UEMybDZfem5WekpkY1BBTlJlN1BmT0RoS0ZUbVphTGpaNjQ4RF…
Is it Worth Adding Veracyte Stock to Your Portfolio Now? - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMipAFBVV95cUxQbl9fR3dtdXJtekkyYTJVX3lzR2pLTDI1b0ZVczA5YTZlUVA4TmdGOWxLc0l1V3E4MV9QWVhvc05mRkxhdnV5Q0t1Q18yZnJNa1E2ZXI4LXo4OHAweFNCSWcyS2Z0ZEtTbVVfUWcybEN0WUVRSVVTbWpGT1YtV0lsQzJjT1hmYi1VQ2lJWm…
Chief Scientific & Medical Officer Of Veracyte Sold 33% Of Their Shares - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi2gFBVV95cUxQNXJjendHeF9pa212c29aZ191LWtZY0JMZFhfQ01OV3dlTElUcEx2REdXUVF1RmViM1g2T0lnUUJWdjgwUFpuc0hUVjF4b3hud3lQOUNIeV9pcmZXTXZKZ1dkSWRTTEVGXy0zbjBZRFVpVVBTbXktY2k2dzJtSmIxMG9LT3BkNUFXQ1JOWE…
Veracyte CFO Rebecca Chambers sells $157,394 in VCYT shares - Investing.com India
<a href="https://news.google.com/rss/articles/CBMiugFBVV95cUxPSElWeWl2MGxTZlZKemUtMFJjMm5yMTBRTlE1R2dWNnk5cnZ5LTctZjlZM29WZm55NGlJQWVzN0tMYVVfZ2JPMmNHVU9pdG8teUhtX0NXZGZCR2RPa2xKSjhkY0pyUlVpX3BTSGFrLTE2MTJiejVyWlUwdmJsUFNsdV9vZGpkSEZvdmVQTF…
Veracyte (VCYT) CCO logs tax withholding, not sale - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiqgFBVV95cUxPbS04X0pWUjJjWElsWXpiU0xLUF9IWm1rNmxRYkZmckV1MWRobF90cS1VY2diQUxFdnBIVDg4ZnE3Y1dXQWtZUjJ6TDlDUEloYzJzRnlkdHNyOFAwNWZCaUxBQUo0N2FnNzVjRkFKSmhlaWJyek9sblpSVzB6cnhZakJSdzVIdGxzZ2x4Qk…
VCYT — Frequently Asked Questions
What is the current share price of Veracyte, Inc. (VCYT)?
As of 2026-09-07 16:24 PDT, Veracyte, Inc. (VCYT) trades at $43.41 on NasdaqGM. Its 52-week range is $28.61 to $60.49.
What is the market capitalisation of VCYT?
Veracyte, Inc. (VCYT) has a market capitalisation of $3.49B on NasdaqGM.
What is the P/E ratio of VCYT?
VCYT trades at a trailing price-to-earnings (P/E) ratio of 31.01. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 2.86.
What is the return on equity (ROE) of VCYT?
VCYT has a return on equity (ROE) of 8.77%. Its return on capital employed (ROCE) is 4.29%.
Is VCYT a good stock to buy?
This page provides a data-driven analysis of Veracyte, Inc. (VCYT), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.